ES2065723T3 - Derivados de carbostirilo y composiciones que los contienen para su uso como agentes de mejora de trastornos de la conciencia, estimulantes del sistema nervioso central o agonistas de receptores sigma. - Google Patents

Derivados de carbostirilo y composiciones que los contienen para su uso como agentes de mejora de trastornos de la conciencia, estimulantes del sistema nervioso central o agonistas de receptores sigma.

Info

Publication number
ES2065723T3
ES2065723T3 ES92107681T ES92107681T ES2065723T3 ES 2065723 T3 ES2065723 T3 ES 2065723T3 ES 92107681 T ES92107681 T ES 92107681T ES 92107681 T ES92107681 T ES 92107681T ES 2065723 T3 ES2065723 T3 ES 2065723T3
Authority
ES
Spain
Prior art keywords
carbostirile
stimulants
consciousness
derivatives
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92107681T
Other languages
English (en)
Inventor
Yasuo Oshiro
Tatsuyoshi Tanaka
Tetsuro Kikuchi
Katsura Tottori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2065723T3 publication Critical patent/ES2065723T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE PRESENTAN DERIVADOS DEL CARBOESTIRIL DE LA FORMULA GENERAL (I) EN LA QUE R1 ES HALOGNO, HIDROXIL, ALCOXIDO INFERIOR, ALQUIL INFERIOR, ALQUENILOXIDO INFERIOR, AMINO, AMINO DE ALCANOIL INFERIOR O ALQUILTIO INFERIOR, R2 ES UN GRUPO FENIL QUE PUEDE OPCIONALMENTE TENER UNO O DOS SUBSTITUYENTES, A ES UN GRUPO ALQUILENO INFERIOR, Y N ES UN ENTERO QUE VALE 1 O 2 EN DONDE EL ENLACE DE CARBONO ENTRE LAS POSICIONES 3 Y 4 DEL ESQUELETO CARBOSTIRIL PUEDEN SER UN ENLACE SIMPLE O UN DOBLE ENLACE, ASI MISMO SE PRESENTAN LAS SALES DE LOS COMPUESTOS Y LOS COMPUESTOS FARMACEUTICOS QUE LOS CONTIENEN Y QUE SON UTILES COMO AGENTES DE MEJORA DE LAS ALTERACIONES DE LA CONSCIENCIA, ESTIMULANTES DEL SISTEMA NERVIOSO CENTRAL O ANTAGONISTAS DEL RECEPTOR SIGMA.
ES92107681T 1991-05-08 1992-05-07 Derivados de carbostirilo y composiciones que los contienen para su uso como agentes de mejora de trastornos de la conciencia, estimulantes del sistema nervioso central o agonistas de receptores sigma. Expired - Lifetime ES2065723T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10239191 1991-05-08

Publications (1)

Publication Number Publication Date
ES2065723T3 true ES2065723T3 (es) 1995-02-16

Family

ID=14326152

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92107681T Expired - Lifetime ES2065723T3 (es) 1991-05-08 1992-05-07 Derivados de carbostirilo y composiciones que los contienen para su uso como agentes de mejora de trastornos de la conciencia, estimulantes del sistema nervioso central o agonistas de receptores sigma.

Country Status (12)

Country Link
US (1) US5656633A (es)
EP (1) EP0512525B1 (es)
JP (1) JP2579263B2 (es)
KR (1) KR0145337B1 (es)
CN (1) CN1042531C (es)
AU (1) AU648890B2 (es)
CA (1) CA2067475C (es)
DE (1) DE69200739T2 (es)
DK (1) DK0512525T3 (es)
ES (1) ES2065723T3 (es)
MX (1) MX9202151A (es)
TW (1) TW205546B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426771T2 (de) * 1993-06-25 2001-06-13 Pola Chemical Industries, Inc. Dopaminreinkorporationshemmer zur behandlung des parkinsonschen syndroms
EP0934932A4 (en) * 1996-08-22 2002-06-26 Meiji Seika Kaisha CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20060223891A1 (en) * 2003-06-13 2006-10-05 Cerep Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
US20070142396A1 (en) * 2005-12-16 2007-06-21 Vela Pharmaceuticals, Inc. Treatment of pain with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof
US20070142395A1 (en) * 2005-12-16 2007-06-21 Vela Pharmaceuticals, Inc. Treatment of sexual dysfunction with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699092A (en) * 1967-01-11 1972-10-17 Eastman Kodak Co Thiazolyl-monoazo-tetrahydroquinoline dyes
US3629266A (en) * 1969-03-03 1971-12-21 Miles Lab (phenyl piperidino alkyl)3 4-dihydrocarbostyrils
FI791926A7 (fi) * 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
JPS5583781A (en) * 1978-12-19 1980-06-24 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative
DE2915250A1 (de) * 1979-04-14 1980-10-30 Basf Ag Salze von alpha -aminoacetaniliden
JPS5649359A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS574974A (en) * 1980-06-11 1982-01-11 Otsuka Pharmaceut Co Ltd Carbostyril derivative
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
DK111387A (da) * 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
JPS63146872A (ja) * 1986-07-08 1988-06-18 Yoshitomi Pharmaceut Ind Ltd ピリミジニルピペラジン化合物
AU639529B2 (en) * 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2718127B2 (ja) * 1988-01-06 1998-02-25 武田薬品工業株式会社 複素環カルボン酸エステルの誘導体
JPH01272524A (ja) * 1988-04-21 1989-10-31 Japan Found Cancer Res 癌化学療法剤
JPH02102568A (ja) * 1988-10-11 1990-04-16 Nec Corp 半導体集積回路装置
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof

Also Published As

Publication number Publication date
CN1069973A (zh) 1993-03-17
CA2067475C (en) 2000-10-10
HK1004549A1 (en) 1998-11-27
CA2067475A1 (en) 1992-11-09
DK0512525T3 (da) 1995-04-24
MX9202151A (es) 1993-08-01
TW205546B (es) 1993-05-11
KR920021532A (ko) 1992-12-18
US5656633A (en) 1997-08-12
AU648890B2 (en) 1994-05-05
EP0512525B1 (en) 1994-11-30
KR0145337B1 (ko) 1998-07-15
JPH05125053A (ja) 1993-05-21
JP2579263B2 (ja) 1997-02-05
CN1042531C (zh) 1999-03-17
AU1526292A (en) 1992-11-12
DE69200739D1 (de) 1995-01-12
DE69200739T2 (de) 1995-05-11
EP0512525A1 (en) 1992-11-11

Similar Documents

Publication Publication Date Title
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
ES2162792T3 (es) Derivados de benzanilida como antagonistas de 5-ht1d.
ES2070253T3 (es) Ciclohexanoles sustituidos utiles como agentes para el sistema nervioso central.
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
ES2157593T3 (es) Derivados de la adenosina heterociclicos sustituidos en n6.
ES2072779T3 (es) Derivados aminoacidos anfoteros.
ES2113368T3 (es) Antagonistas de serotonina.
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2074205T3 (es) Compuestos heterociclicos condensados, su produccion y uso.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2079774T3 (es) Derivados de indolopirrolocarbazol.
ES2055056T3 (es) Derivados de pirimidopirimidina.
AR011229A1 (es) Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.
ES2046202T3 (es) Un procedimiento para preparar un analogo de distamicina a.
ES2040784T3 (es) Composicion de aditivo.
MX167801B (es) Inhibidor de la corrosion para combustibles liquids
ES2037753T3 (es) Compuestos heterociclicos y su preparacion y uso.
ES2055035T3 (es) Un proceso para la preparacion de un glicosido de antraciclina.
ES2084996T3 (es) Piperazinas sustituidas utiles como agentes para el sistema nervioso central.
UY23718A1 (es) Procedimiento para la preparacion de derivados de octahidro- fenantreno
ES2075004T3 (es) Derivados de pirimidina, procedimientos para su produccion y composiciones herbicidas que los contienen.
ES2057322T3 (es) Derivados de amida de aminoacido substituidos, su fabricacion y uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 512525

Country of ref document: ES